Safe prescribing information for children in Canada often hard to find
Key points
- Accurate, safe prescribing information for children is often unavailable to doctors in Canada because pharmaceutical companies will not disclose information to Health Canada, states an editorial in CMAJ (Canadian Medical Association Journal).
- Health professionals in Canada as well as other countries such as Japan and Australia, unlike their colleagues in the United States and Europe, do not have access to the same body of evidence regarding pediatric dosing.
- "As a consequence, Canadian children and youth may fall victim to medication errors and mistreatment simply because of limited access to information about pediatric drugs," writes Dr.
- Many drugs in the US that have specific pediatric labeling are described in Canada as having "insufficient evidence."
Accurate, safe prescribing information for children is often unavailable to doctors in Canada because pharmaceutical companies will not disclose information to Health Canada, states an editorial in CMAJ (Canadian Medical Association Journal).
Health professionals in Canada as well as other countries such as Japan and Australia, unlike their colleagues in the United States and Europe, do not have access to the same body of evidence regarding pediatric dosing.
"As a consequence, Canadian children and youth may fall victim to medication errors and mistreatment simply because of limited access to information about pediatric drugs," writes Dr. Paul Hébert, Editor-in-Chief, CMAJ, with coauthors.
Many drugs in the US that have specific pediatric labeling are described in Canada as having "insufficient evidence."
"Children are not little adults," state the authors. "Pediatric labelling should go well beyond simply adjusting adult doses to a pediatric weight, because this is inappropriate and potentially dangerous."
They cite as an example the increased suicide risk from early off-label prescribing of selective serotonin reuptake inhibitors guided only by data in adults.
While the pharmaceutical industry maintains that pediatric markets are small and not profitable, the US and Europe have introduced financial incentives to encourage research in children. The US Pediatric Research Equity Act requires drug companies to conduct studies and submit results to the US Food and Drug Administration for drugs they expect will be used in children.
"In line with recommendations of the World Health Organization, we need international harmonization of laws to ensure that appropriate incentives are in place to promote pediatric research necessary for pediatric indications and prescribing information," write the authors.
They conclude with a call to politicians to enact strict legislation similar to that in the US to protect Canadian children.
###
Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Children's Health →
NewsSLU research finds hospital physicians fail to identify, address weight issues in children
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist. "Physicians…
6 August 2015
NewsEating habits matter most with overweight children
A recent study looks at why some children put on weight faster than others. The study's goal is to identify factors that can lead to obesity. Assistant Professor Silje Steinsbekk and Professor Lars Wichstrøm at the…
18 July 2015
NewsMillions of children's lives saved through low-cost investments
More than 34 million children's lives have been saved since 2000 because of investments in child health programs at a cost of as little as $4,205 per child, according to a new analysis in The Lancet. This analysis…
